Due to its recently discovered role as causal agent of a molecular subtype of gastric cancer [7], we decided to test the effect of HSF2 in EBV life cycle using EBV-associated gastric cancer primary cells obtained from patient-derived- xenografts (PDXs). The gene discussed is HSF2; the disease is gastric cancer.